Advanced search
Publication Cover
Expert Review of Anticancer Therapy Volume 13, 2013 - Issue 11
Submit an article Journal homepage
221
Views
3
CrossRef citations to date
0
Altmetric
Clinical Trial Report

Clinical practice-changing trials: the HERA study paradigm

Dimitrios ZardavasMedical Oncology Department, Institut Jules Bordet, Br.E.A.S.T. Data Centre Brussels, Blvd de Waterloo, 121 (7th Floor), 1000 Brussels, Belgium
,
Felipe AdesMedical Oncology Department, Institut Jules Bordet, Br.E.A.S.T. Data Centre Brussels, Blvd de Waterloo, 121 (7th Floor), 1000 Brussels, Belgium
&
Evandro de AzambujaMedical Oncology Department, Institut Jules Bordet, Br.E.A.S.T. Data Centre Brussels, Blvd de Waterloo, 121 (7th Floor), 1000 Brussels, BelgiumCorrespondence[email protected]
Pages 1249-1256 | Published online: 10 Jan 2014

References

  • Yarden Y, Sliwkowski MX. Untangling the ErbB signalling network. Nat. Rev. Mol. Cell Biol. 2(2), 127–137 (2001).
  • Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235(4785), 177–182 (1987).
  • Hudis CA. Trastuzumab--mechanism of action and use in clinical practice. N. Engl. J. Med. 357(1), 39–51 (2007).
  • Slamon DJ, Leyland-Jones B, Shak S et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N. Engl. J. Med. 344(11), 783–792 (2001).
  • Piccart-Gebhart MJ, Procter M, Leyland-Jones B et al. Trastuzumab after Adjuvant Chemotherapy in HER2-Positive Breast Cancer. N. Engl. J. Med. 353(16), 1659–1672 (2005).
  • Romond EH, Perez EA, Bryant J et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N. Engl. J. Med. 353(16), 1673–1684 (2005).
  • Smith I, Procter M, Gelber RD et al. 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. Lancet 369(9555), 29–36 (2007).
  • Gianni L, Dafni U, Gelber RD et al. Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial. Lancet Oncol. 12(3), 236–244 (2011).
  • Goldhirsch A, Gelber RD, Piccart-Gebhart MJ et al. 2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trial. Lancet 382(9897), 1021–1028 (2013).
  • Joensuu H. Duration of adjuvant trastuzumab: shorter beats longer. Lancet 382(9897), 1010–1011 (2013).
  • Pivot X, Romieu G, Debled M et al. 6 months versus 12 months of adjuvant trastuzumab for patients with HER2-positive early breast cancer (PHARE): a randomised phase 3 trial. Lancet Oncol. 14(8), 741–748 (2013).
  • Bria E, Cuppone F, Fornier M et al. Cardiotoxicity and incidence of brain metastases after adjuvant trastuzumab for early breast cancer: the dark side of the moon? a meta-analysis of the randomized trials. Breast Cancer Res. Treat. 109(2), 231–239 (2007).
  • Pestalozzi BC, Holmes E, de Azambuja E et al. CNS relapses in patients with HER2-positive early breast cancer who have and have not received adjuvant trastuzumab: a retrospective substudy of the HERA trial (BIG 1-01). Lancet Oncol. 14(3), 244–248 (2013).
  • De Azambuja E, Bedard PL, Suter T, Piccart-Gebhart M. Cardiac toxicity with anti-HER-2 therapies: what have we learned so far? Target Oncol. 4(2), 77–88 (2009).
  • Procter M, Suter TM, de Azambuja E et al. Longer-Term Assessment of Trastuzumab-Related C ardiac Adverse Events in the Herceptin Adjuvant (HERA) Trial. J. Clin. Oncol. 28(21), 3422–3428 (2010).
  • De Azambuja E, Procter M, van Veldhuisen DJ et al. Long-term (8 years) assessment of trastuzumab-related cardiac events in the HERA trial. Presented at: 2013 ASCO Annual Meeting. J. Clin. Oncol. 31( Suppl.), Abstract 525 (2013).
  • Azim HA, Metzger-Filho O, Azambuja E et al. Pregnancy occurring during or following adjuvant trastuzumab in patients enrolled in the HERA trial (BIG 01-01). Breast Cancer Res. Treat. 133(1), 387–391 (2012).
  • Yu J, Dabbs DJ, Shuai Y, Niemeier LA, Bhargava R. Classical-type invasive lobular carcinoma with HER 2 overexpression: clinical, histologic, and hormone receptor characteristics. Am. J. Clin. Pathol. 136(1), 88–97 (2011).
  • Metzger-Filho O, Procter M, de Azambuja E et al. Magnitude of trastuzumab benefit in patients with HER 2-positive, invasive lobular breast carcinoma: results from the HERA trial. J. Clin. Oncol. 31(16), 1954–1960 (2013).
  • Adami H-O, Malker B, Holmberg L, Persson I, Stone B. The relation between survival and age at diagnosis in breast cancer. N. Engl. J. Med. 315(9), 559–563 (1986).
  • Colleoni M. Role of endocrine responsiveness and adjuvant therapy in very young women (below 35 years) with operable breast cancer and node negative disease. Ann. Oncol. 17(10), 1497–1503 (2006).
  • Partridge AH, Gelber S, Piccart-Gebhart MJ et al. Effect of age on breast cancer outcomes in women with human epidermal growth factor receptor 2-positive breast cancer: results from a herceptin Adjuvant trial. J. Clin. Oncol. 31(21), 2692–2698 (2013).
  • Zabaglo L, Stoss O, Ruschoff J et al. HER2 staining intensity in HER2-positive disease: relationship with FISH amplification and clinical outcome in the HERA trial of adjuvant trastuzumab. Ann. Oncol. ( doi:10.1093/annonc/mdt275) (2013) ( Epub ahead of print).
  • Perez EA, Suman VJ, Davidson NE et al. Sequential versus concurrent trastuzumab in adjuvant chemotherapy for breast cancer. J. Clin. Oncol. 29(34), 4491–4497 (2011).
  • Slamon D, Eiermann W, Robert N et al. Adjuvant trastuzumab in HER2-positive breast cancer. N. Engl. J. Med. 365(14), 1273–1283 (2011).
  • Joensuu H, Bono P, Kataja V et al. Fluorouracil, epirubicin, and cyclophosphamide with either docetaxel or vinorelbine, with or without Trastuzumab, as adjuvant treatments of breast cancer: final results of the finher trial. J. Clin. Oncol. 27(34), 5685–5692 (2009).
  • Spielmann M, Roché H, Delozier T et al. Trastuzumab for patients with axillary-node-positive breast cancer: results of the FNCLCC-PACS 04 trial. J. Clin. Oncol. 27(36), 6129–6134 (2009).
  • Zardavas D, Cameron D, Krop IE, Piccart M. Beyond trastuzumab and lapatinib: new treatment options for HER2-positive breast cancer. Am. Soc. Clin. Oncol. Educ. Book 2013, 2–11 (2013).
  • Zardavas D, Bozovic-Spasojevic I, de Azambuja E. Dual human epidermal growth factor receptor 2 blockade. Curr. Opin. Oncol. 24(6), 612–622 (2012).
  • Blackwell KL, Burstein HJ, Storniolo AM et al. Randomized study of lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory m etastatic breast cancer. J. Clin. Oncol. 28(7), 1124–1130 (2010).
  • Baselga J, Cortés J, Kim S-B et al. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N. Engl. J. Med. 366(2), 109–119 (2012).
  • Gianni L, Pienkowski T, Im Y-H et al. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial. Lancet Oncol. 13(1), 25–32 (2012).
  • Baselga J, Bradbury I, Eidtmann H et al. Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial. Lancet 379(9816), 633–640 (2012).
  • Tomasello G, de Azambuja E, Dinh P, Snoj N, Piccart-Gebhart M. Jumping higher: is it still possible? The ALTTO trial challenge. Expert Rev. Anticancer. Ther. 8(12), 1883–1890 (2008).
  • Stern HM. Improving treatment of HER2-Positive cancers: opportunities and challenges. Sci. Transl. Med. 4(127), 127rv2 (2012).
  • Ignatiadis M, Rothé F, Chaboteaux C et al. HER2-positive circulating tumor cells in breast cancer. PLoS ONE 6(1), e15624 (2011).
  • Zardavas D, Baselga J, Piccart M. Emerging targeted agents in metastatic breast cancer. Nat. Rev. Clin. Oncol. 10(4), 191–210 (2013).
  • Rodrigues MJ, Peron J, Frénel J-S et al. Benefit of adjuvant trastuzumab-based chemotherapy in T1ab node-negative HER2-overexpressing breast carcinomas: a multicenter retrospective series. Ann. Oncol. 24(4), 916–924 (2013).
  • Goldhirsch A, Winer EP, Coates AS et al. Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2013. Ann. Oncol. 24(9), 2206–2223 (2013). http://annonc.oxfordjournals.org/cgi/doi/10.1093/annonc/mdt303 ( Accessed 6 August 2013)

Website

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.